Rheostat is working to develop novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. Its central thesis is that the degradation of toxic cellular components is a fundamental node of biology. The mutations that impair these clearance pathways have been linked with multiple neurodegenerative diseases, many of which are associated with cognitive impairment like Parkinson's disease. The company is working to leverage its understanding of these pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/26/18 | $23,000,000 | Series A |
AbbVie Biotech Ventures Alexandria Real Estate Equities Amgen Business Development Dementia Discovery Fund Mayo Clinic MRL Ventures Fund  SV Health Investors | undisclosed |
